JNJ vs KMDA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JNJ presents a dichotomy between strong profitability and deteriorating fundamental health, evidenced by a weak Piotroski F-Score of 3/9. While the company maintains an impressive ROE of 35.03% and a consistent history of earnings beats, the current price of $237.96 trades at a significant premium to its Graham Number of $91.72. Growth remains robust on a YoY basis, but bearish insider sentiment and a very weak technical trend (10/100) suggest immediate headwinds. The stock is fundamentally sound in terms of earnings power but shows signs of operational inefficiency or declining quality in its deterministic health metrics.
KMDA presents a dichotomy between a fortress-like balance sheet and poor deterministic value metrics. While the Piotroski F-Score of 4/9 indicates stable health and the Debt/Equity ratio (0.04) is exceptionally low, the stock trades at a significant premium to its Graham Number ($6.06) and Intrinsic Value ($2.45). The attractive PEG ratio (0.63) suggests growth is undervalued, but this is offset by negative YoY earnings growth (-14.10%) and a bearish technical trend.
Compare Another Pair
Related Comparisons
JNJ vs KMDA: Head-to-Head Comparison
This page compares Johnson & Johnson (JNJ) and Kamada Ltd. (KMDA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.